Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | HTR7 | P34969 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 3/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | DRD1 | P21728 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | DRD5 | P21918 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 4/20 | 0.38 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.38 |
| ▸ | ANPEP | P15144 | 3/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
| ▸ | RET | P07949 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | HRH1 | P35367 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6906970 | 0.78 | HTR1A (0.46) | HTR1AHTR7HTR2ADRD2HTR2C | |
| SCHEMBL18828495 | 0.75 | HTR1A (0.50) | HTR1AHTR7IDO1NOTUMHTR2C | |
| SCHEMBL24120085 | 0.74 | HTR2C (0.51) | HTR1AHTR7HTR2C | |
| SCHEMBL31379414 | 0.74 | CYP2A6 (0.46) | HTR1ACYP2A6DRD2DRD1DRD4 | |
| Hydrochloric Acid SCHEMBL23780213 | 0.73 | HTR2C (0.53) | HTR1AHTR7HTR2C | |
| SCHEMBL8778448 | 0.73 | CES1 (0.53) | — | |
| SCHEMBL250734 | 0.72 | CYP2A6 (0.65) | HTR2ACYP2A6DRD2DRD1DRD4 | |
| SCHEMBL2771201 | 0.71 | CYP2A6 (0.48) | CYP2A6DRD2DRD1DRD4DRD5 | |
| SCHEMBL6906227 | 0.71 | DRD1 (0.47) | HTR1AHTR7HTR2ACYP2A6DRD2 | |
| SCHEMBL1861381 | 0.71 | ADRA2A (0.48) | CYP2A6DRD2DRD1DRD4DRD5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220010258-A1 | DEVICE THAT CAN SERVE AS A HEMATO-ENCEPHALITIC BARRIER MODEL | CENTRE HOSPITALIER UNIVERSITAIRE DE POITIERS (FR) | 2022-01-13 | — | — | US | disclosed |
| EP-3665264-A1 | DEVICE THAT CAN SERVE AS A HEMATO-ENCEPHALITIC BARRIER MODEL | Université De Poitiers (FR) | 2020-06-17 | — | — | EP | disclosed |
| WO-2019030380-A1 | DEVICE THAT CAN SERVE AS A HEMATO-ENCEPHALITIC BARRIER MODEL | UNIVERSITE DE POITIERS (FR) | 2019-02-14 | — | — | WO | disclosed |
| US-20160244457-A1 | SELECTIVE EFFLUX INHIBITORS AND RELATED PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATMENT | UNIV KANSAS (US) | 2016-08-25 | — | — | US | disclosed |
| US-20150328180-A1 | Composition | SLOTERVAART PARTICIPATIES BV (NL) | 2015-11-19 | — | — | US | disclosed |
| CN-103446162-B | 3 β, 20 (S), 21-trihydroxy dammarane-24-alkene is preparing the purposes in multidrug resistance reversing agent | FUDAN UNIVERSITY (CN) | 2015-10-28 | — | — | CN | disclosed |
| CN-103371992-B | (E)-nitrogen-(4-cinnamamide butyl) Benzoylamide is preparing the application in antitumor drug | FUDAN UNIVERSITY (CN) | 2015-08-19 | — | — | CN | disclosed |
| US-9089544-B2 | Composition | SLOTERVAART PARTICIPATIES BV (NL) | 2015-07-28 | — | — | US | disclosed |
| US-20150197526-A1 | SELECTIVE EFFLUX INHIBITORS AND RELATED PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATMENT | UNIVERSITY OF KANSAS | 2015-07-16 | — | — | US | disclosed |
| US-9056111-B1 | Selective efflux inhibitors and related pharmaceutical compositions and methods of treatment | STC.UNM (US) | 2015-06-16 | — | — | US | disclosed |
| US-20090054503-A1 | COMPOSITION | SLOTERVAART PARTICIPATIES BV (NL) | 2009-02-26 | — | — | US | disclosed |
| EP-2011489-A2 | Method to inhibit ischemia and reperfusion injury | Gottlieb, Roberta (US) | 2009-01-07 | — | — | EP | disclosed |
| US-20060216341-A1 | Compositions for treating drug resistance | BCCA BRANCH (CA) | 2006-09-28 | — | — | US | disclosed |
| EP-1617828-A2 | NANO-SIZED VEHICLES TRANSPORTING A THERAPEUTIC AGENT AND AT LEAST ONE DRUG RESISTANCE MODULATOR FOR THE TREATMENT OF MULTI DRUG RESISTANCE | Celator Pharmaceuticals, Inc. (US) | 2006-01-25 | — | — | EP | disclosed |
| EP-1523310-A2 | METHOD TO INHIBIT ISCHEMIA AND REPERFUSION INJURY | The Scripps Research Institute (US) | 2005-04-20 | — | — | EP | disclosed |
| WO-2004087094-A2 | NANO-SIZED VEHICLES TRANSPORTING A THERAPEUTIC AGENT AND AT LEAST ONE DRUG RESISTANCE MODULATOR FOR THE TREATMENT OF MULTI DRUG RESISTANCE | CELATOR PHARMACEUTICALS, INC. (US) | 2004-10-14 | — | — | WO | disclosed |
| WO-2004004702-A2 | METHOD TO INHIBIT ISCHEMIA AND REPERFUSION INJURY | THE SCRIPPS RESEARCH INSTITUTE (US) | 2004-01-15 | — | — | WO | disclosed |
| US-20030031715-A1 | Pharmaceutical applications of hydrotropic agents, polymers thereof, and hydrogels thereof | PURDUE RESEARCH FOUNDATION | 2003-02-13 | — | — | US | disclosed |
| WO-2002030466-A2 | PHARMACEUTICAL APPLICATIONS OF HYDROTROPIC AGENTS, POLYMERS THEREOF, AND HYDROGELS THEREOF | PURDUE RESEARCH FOUNDATION (US) | 2002-04-18 | — | — | WO | disclosed |
| WO-1999017757-A1 | USE OF P-GLYCOPROTEIN (Pgp) INHIBITORS IN THE TREATMENT OF CANCER | DZIEGLEWSKA HANNA EVA (GB) | 1999-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150197526-A1 | SELECTIVE EFFLUX INHIBITORS AND RELATED PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATMENT | ABCB1, ABCG2, ABCC5 | HTR1A 853/4885HTR7 1955/4885HTR2A 1046/4885 |
| US-20030031715-A1 | Pharmaceutical applications of hydrotropic agents, polymers thereof, and hydrogels thereof | HMGB2, HTT, ABCG2 | HTR1A 547/4885HTR7 114/4885HTR2A 215/4885 |
| US-20160244457-A1 | SELECTIVE EFFLUX INHIBITORS AND RELATED PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATMENT | ABCB1, ABCG2, ABCC5 | HTR1A 853/4885HTR7 1955/4885HTR2A 1046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.